{"filings":[{"id":667396,"accession_number":"0001193125-26-239230","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2026-05-26T20:02:57+00:00","items":["5.07","9.01"],"status":"ready","headline":"Spruce Biosciences annual meeting results: directors elected, say-on-pay passed, frequency set to every year","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual meeting held May 21, 2026; quorum of 65.86% (903,893 of 1,372,278 shares outstanding).","Class III directors elected: Michael Grey (276,159 for), Camilla V. Simpson (191,284 for), Javier Szwarcberg (293,098 for).","Ratification of BDO USA as auditor for FY 2026 approved: 880,984 for, 16,851 against.","Advisory say-on-pay approved with 187,027 for, 111,274 against, 1,573 abstentions (62.7% approval on votes cast).","Stockholders voted for annual advisory votes on executive compensation; company will hold annual say-on-pay until 2032."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50445,"accession_number":"0001193125-26-220648","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2026-05-13T12:05:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q1 net loss $12.3M; cash $54.1M (Mar 31), $107.3M (Apr 30)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.3M ($8.94 per share) for Q1 2026; R&D expenses $7.6M, G&A $4.4M.","Cash $54.1M at March 31, 2026; preliminary cash $107.3M at April 30, 2026; runway into H2 2027.","Closed $69.0M diluted public offering in April 2026; secured up to $50M term loan from Avenue Capital (Tranche 1: $15M funded).","BLA submission for TA-ERT (MPS IIIB) on track for Q4 2026; long-term data showed durable HS reduction and cognitive stabilization."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94672,"accession_number":"0001193125-26-167332","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2026-04-22T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Spruce Biosciences prices $69M public offering of common stock and pre-funded warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$69M from 1.33M shares at $50/share and 50K pre-funded warrants at $49.99.","Underwriters' option for 180K additional shares exercised in full on April 21, 2026.","Offering expected to close April 22; net proceeds for working capital and general corporate purposes.","Pre-funded warrants exercisable immediately at $0.01 per share, with a 4.99% beneficial ownership cap."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107230,"accession_number":"0001193125-26-117888","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"Spruce terminates Kaken collaboration for tildacerfont in Japan; reports FY 2025 results, BLA on track","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Termination of Collaboration and License Agreement with Kaken effective March 31, 2026; no penalties incurred.","FY 2025 net loss $39.0M on operating expenses $36.5M; cash $48.9M excluding $15M debt tranche from Avenue Capital.","BLA submission for TA-ERT (MPS IIIB) on track for Q4 2026; FDA confirmed potential for accelerated approval.","Appointed Dale Hooks as Chief Commercial Officer; secured up to $50M loan facility from Avenue Capital Group.","R&D expenses fell to $19.5M from $46.4M, driven by cessation of tildacerfont development for CAH."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107229,"accession_number":"0001193125-26-097561","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["1.01","1.02","2.02","5.02","9.01"],"status":"ready","headline":"Spruce Biosciences reports FY2025 net loss of $39M; BLA for TA-ERT on track for Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $39.0M for 2025 vs $53.0M in 2024; R&D expenses fell to $19.5M on cessation of CAH program.","Cash and equivalents $48.9M at Dec 31, 2025, plus $15M drawn from Avenue Capital loan; runway into early 2027.","BLA submission for TA-ERT (MPS IIIB) expected Q4 2026 after positive FDA Type B meetings on surrogate endpoint.","Appointed Dale Hooks as CCO; secured up to $50M growth capital from Avenue Capital with initial $15M funded in Jan 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107228,"accession_number":"0001193125-26-039399","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Spruce Biosciences reports long-term TA-ERT data stabilizing cognition and motor skills in MPS IIIB","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["TA-ERT normalized CSF HS-NRE and stabilized Bayley-III cognitive scores over up to 6 years vs decline in natural history.","VABS-II analysis showed stabilization of receptive/expressive communication and fine/gross motor skills.","Sibling case study: treated child at 12.1 years spoke words and self-fed; untreated at 11.7 years was nonverbal and dependent.","Safety consistent with ICV route; ~6,000 doses administered to 22 patients without new safety signals.","Spruce plans to advance TA-ERT through BLA submission and potential FDA approval for MPS IIIB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107227,"accession_number":"0001193125-26-007038","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["1.01","2.02","2.03","3.02","7.01","9.01"],"status":"ready","headline":"Spruce Biosciences secures up to $50M loan facility from Avenue Capital; initial $15M funded","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Loan facility up to $50M from Avenue Capital; initial $15M tranche funded on Jan 9, 2026.","Additional $35M available in 3 tranches tied to regulatory/commercial milestones for TA-ERT (MPS IIIB).","Preliminary unaudited cash & equivalents ~$48.9M as of Dec 31, 2025; combined with initial tranche extends runway into 2027.","Loan matures July 1, 2029; interest rate greater of prime+5.25% or 12.25%; no financial covenants.","Warrant issued for up to $3.2M in common stock; exercise price lesser of $84.75 or next equity round price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123564,"accession_number":"0001193125-25-318488","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-12-15T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Spruce Biosciences appoints Keli Walbert to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Keli Walbert appointed as Class I Director effective December 11, 2025, term expiring at 2027 annual meeting.","Granted nonstatutory stock option to purchase 3,400 shares vesting monthly over three years.","Annual cash retainer: $40,000 as director; $5,000 for Compensation Committee (increasing to $5,500 in 2026).","Eligible for annual option grant of 1,700 shares starting with 2026 annual meeting, vesting over one year.","Entered into standard indemnification agreement; no related-party transactions disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123563,"accession_number":"0001193125-25-317532","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Spruce Biosciences reprices underwater options to $104.13; director resigns","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Director Tiba Aynechi resigned from board and Compensation Committee effective Dec 11, 2025, no disagreement.","Board approved repricing of 30,174 underwater options to $104.13 per share (30-day trailing VWAP).","CEO Javier Szwarcberg holds 11,666 repriced options (original $344.25); CFO Samir Gharib holds 6,131 (original $122.65–$1,506).","Repriced options require 12-month retention, FDA approval, or change in control to exercise at reduced price; vesting unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123562,"accession_number":"0001193125-25-274216","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Q3 net loss $8.2M; FDA BTD for TA-ERT; $50M placement; BLA on track Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA granted Breakthrough Therapy Designation for TA-ERT (MPS IIIB); BLA submission on track for Q1 2026.","Completed $50M private placement in Oct 2025; cash plus proceeds expected to fund ops into Q4 2026.","Q3 2025 net loss $8.2M vs $8.7M YoY; R&D $5.0M (down 24% YoY) due to tildacerfont program cessation.","Cash $10.7M at Sep 30, 2025; common shares 563,491 pre-placement; Oct placement added 502,181 shares and 233,144 prefunded warrants."],"consensus_eps_estimate":-14.2137,"consensus_eps_actual":-41.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123561,"accession_number":"0001193125-25-242488","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-10-17T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Bali Muralidhar resigns from Spruce Biosciences board, effective Oct 15","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Bali Muralidhar, Ph.D. resigned from the Board and compensation committee on October 15, 2025.","Resignation is not due to any disagreement with the Company on operations, policies, or practices.","No replacement named; Board size reduced by one."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123560,"accession_number":"0001193125-25-234516","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-10-08T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Spruce Biosciences raises $50M via stock and pre-funded warrants; BLA submission set for Q1 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Private placement: 502,181 shares at $68.00 and pre-funded warrants for 233,144 shares; gross proceeds ~$50M; closing expected Oct 9, 2025.","Pre-funded warrants exercisable at $0.01 for 5 years, subject to 9.99% beneficial ownership limitation.","Company to file resale registration statement within 20 days after closing.","Pipeline update: TA-ERT for Sanfilippo Syndrome Type B BLA submission planned for Q1 2026; potential US commercial launch in late 2026.","Placement agents: Leerink Partners, Citizens Capital Markets, H.C. Wainwright, Oppenheimer & Co.; 6% fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140241,"accession_number":"0000950170-25-108868","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q2 net loss $2.1M; TA-ERT BLA for MPS IIIB on track Q1 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.1M for Q2 2025 vs $9.2M in Q2 2024; cash $16.4M expected to fund through end of 2025.","Integrated TA-ERT data shows CSF HS-NRE reduced 91.5 ng/mL at 240 weeks (p<0.0001); cognition stabilized vs decline in untreated.","First patient dosed in Phase 2 TAMARIND trial of tildacerfont for MDD; topline results expected 1H 2026.","BLA submission for TA-ERT under accelerated approval pathway anticipated Q1 2026; potential first disease-modifying therapy for MPS IIIB.","Nasdaq relisting expected after maintaining minimum bid price for 20 consecutive trading days following 1-for-75 reverse stock split."],"consensus_eps_estimate":-19.5075,"consensus_eps_actual":-27.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140240,"accession_number":"0000950170-25-098340","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-07-24T23:59:59+00:00","items":["3.03","5.03","5.07","7.01","9.01"],"status":"ready","headline":"Spruce Biosciences to effect 1-for-75 reverse stock split on Aug 4 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split effective 5:00 p.m. ET on August 4, 2025; shares trade split-adjusted on OTC Pink on August 5.","Outstanding shares reduce from ~42.2M to ~0.6M; no fractional shares issued, cash payments in lieu.","Stock will return to Nasdaq Capital Market if minimum bid price is met for 20 consecutive trading days after effective date.","Stockholders approved reverse split at annual meeting on July 22; board set ratio at 1:75."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157896,"accession_number":"0000950170-25-085144","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"Spruce Biosciences wins Nasdaq appeal; must regain bid price compliance by Aug 5","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq delisting notice April 22, 2025; stock moved to OTC Pink on April 29, 2025.","On June 9, 2025, Nasdaq Hearings Panel accepted appeal; stock may resume on Nasdaq Capital Market if compliance met by August 5, 2025.","Panel retains jurisdiction until October 20, 2025; any future non-compliance must be reported to the panel.","Company seeks stockholder approval for reverse stock split (1:50 to 1:100) at July 22, 2025 annual meeting to cure bid price deficiency."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157895,"accession_number":"0000950170-25-078590","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["1.01","5.03","3.02","3.03","5.08","8.01","9.01"],"status":"ready","headline":"Spruce Biosciences issues Series A Preferred with 22M votes to Executive Chair to enable reverse stock split vote","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold one share of Series A Preferred to Executive Chair Michael Grey for $100; shares have 22,000,000 votes on reverse stock split proposals only.","Series A votes must mirror common stock vote proportion on reverse split; abstentions/broker non-votes excluded, reducing their effect.","Series A automatically redeemed upon stockholder approval of reverse split; also redeemable at Board's discretion.","Company sets 2025 Annual Meeting for July 22, 2025; record date May 30; stockholder proposals due June 5.","Stock trades on OTC Pink since April 29; reverse split likely aimed at regaining exchange listing compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157894,"accession_number":"0000950170-25-064429","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q1 net loss $14.0M; cash runway to end 2025; TA-ERT BLA in 1H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2025 net loss $14.0M vs $11.6M YoY; R&D includes $5.7M for SPR202 acquisition.","Cash and equivalents $25.6M, expected to fund current operating plan through end of 2025.","TA-ERT for MPS IIIB: BLA submission to FDA expected in 1H 2026; FDA confirmed HS-NRE as surrogate endpoint for accelerated approval.","Tildacerfont Phase 2 TAMARIND MDD study topline results expected 1H 2026; HMNC funding and conducting study.","Stock now trades on OTC Pink under SPRB after NYSE delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157893,"accession_number":"0000950170-25-058863","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-04-25T23:59:59+00:00","items":["2.05","3.01","9.01"],"status":"ready","headline":"Spruce Biosciences cuts 55% workforce; Nasdaq to delist stock on April 29","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of 55% approved by Board; estimated $0.9M cash charges in Q2 2025.","Reduction prioritizes development of tralesinidase alfa for Sanfilippo Syndrome Type B.","Nasdaq delisting notice received April 22; trading suspended at open on April 29, 2025.","Stock expected to trade OTC under SPRB; appealing to Hearings Panel; seeking reverse stock split at annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157892,"accession_number":"0000950170-25-053944","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-04-15T23:59:59+00:00","items":["2.02","9.01","7.01"],"status":"ready","headline":"Spruce Biosciences acquires TA-ERT for MPS IIIB; BLA submission planned 1H 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired exclusive worldwide license for tralesinidase alfa from BioMarin for Sanfilippo Syndrome Type B, a fatal neurodegenerative disease.","FDA confirmed HS-NRE biomarker may reasonably predict clinical benefit and could support accelerated approval.","BLA submission for TA-ERT anticipated in first half of 2026; fast-track, orphan, and rare pediatric designations granted.","Cash and cash equivalents $38.8M as of Dec 31, 2024; expected cash runway through end of 2025.","42.2M shares outstanding, 21.4M reserved for warrants and equity as of Dec 31, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157891,"accession_number":"0000950170-25-048726","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2025-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences files late filing notice for 2024 10-K; includes preliminary estimates","summary_kind":"llm","event_type":"regulatory","confidence":"low","bullets":["Spruce Biosciences filed a Notification of Late Filing (NT 12b-25) for its 2024 Form 10-K on March 31, 2025.","The NT 12b-25 contains preliminary estimates of results of operations and financial condition for fiscal year 2024.","The company is an emerging growth company trading on Nasdaq Capital Market under symbol SPRB."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193163,"accession_number":"0000950170-24-140833","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-12-27T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Spruce Biosciences CMO departing Dec 31; Kirk Ways named interim CMO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Ralph Charlton III's employment ends Dec 31, 2024; severance includes $343,200 lump sum plus 9 months COBRA.","Dr. Kirk Ways (73), Board member since June 2021, appointed interim CMO effective Dec 20, 2024.","Ways previously served as interim CMO of MBX Biosciences and Development Head at Janssen.","Severance amount equals 9 months of base salary at $343,200 paid as lump sum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193162,"accession_number":"0000950170-24-134969","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Spruce Biosciences discontinues tildacerfont CAH program after Phase 2b miss","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b CAHmelia-204 missed primary endpoint: placebo-adjusted GC dose reduction of 0.7mg HCe (p=0.7).","98% compliance; no serious adverse events reported in CAHmelia-204.","Phase 2 CAHptain-205 showed trend of larger A4 reductions at higher BID doses; no drug-related SAEs.","Company discontinuing both trials, winding down tildacerfont investment, and evaluating strategic options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193161,"accession_number":"0000950170-24-124436","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences reports Q3 2024 net loss of $8.7M; cash runway through end of 2025; topline data expected Dec 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.7M in Q3 2024 ($29.5M nine months); cash and equivalents $60.1M as of Sept 30, 2024.","R&D expenses fell to $6.6M (Q3 2024) from $13.5M (Q3 2023) due to study terminations and completions.","Collaboration revenue of $0.6M in Q3 2024 vs $3.1M a year ago, from Kaken Pharmaceutical partnership.","Topline results from CAHmelia-204 (adult CAH) and CAHptain-205 (adult & pediatric CAH) trials expected December 2024.","End-of-Phase 2 meeting with FDA for tildacerfont anticipated in first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":4214000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193160,"accession_number":"0000950170-24-117786","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Spruce Biosciences receives Nasdaq bid-price extension to April 21, 2025; moves to Capital Market","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq extension until April 21, 2025 to meet $1.00 minimum bid price.","Stock transfer from Nasdaq Global Select to Capital Market effective Oct 28, 2024.","Must maintain closing bid >=$1.00 for 10 consecutive business days before deadline.","May consider reverse stock split; failure to comply could lead to delisting.","No immediate impact on listing; company intends to monitor bid price."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209536,"accession_number":"0000950170-24-095417","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q2 net loss $9.2M; cash $69.7M; MDD collaboration with HMNC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $9.2M for Q2 2024 vs $12.8M in Q2 2023; operating expenses down to $11.6M.","Cash $69.7M as of June 30, 2024, expected to fund operations through end of 2025.","Entered collaboration with HMNC to develop tildacerfont for major depressive disorder; HMNC funds Phase 2 study.","Topline data from CAHmelia-204 and CAHptain-205 trials expected in Q4 2024.","Collaboration revenue $1.6M from Kaken agreement, down from $2.2M in Q2 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":3612000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227624,"accession_number":"0000950170-24-074990","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Spruce Biosciences designated back-up bidder for Avexitide assets, net purchase price $34.7M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Entered stalking horse agreement June 13 for Avexitide assets; initial purchase price $10M.","After auction June 17, Spruce became back-up bidder; net purchase price $34.7M (after $0.3M fee credit).","Sale to winning bidder subject to Bankruptcy Court approval at hearing scheduled June 26, 2024.","If winning bidder fails to close, Spruce must acquire assets; otherwise receives $0.3M termination fee.","Spruce also assumes specified contractual cure amounts up to $0.3M if it becomes buyer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227623,"accession_number":"0000950170-24-067650","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-06-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Spruce Biosciences Phase 2 POWER trial shows tildacerfont reduces DHEAS (p=0.020) and increases SHBG (p=0.012) in PCOS","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["27 women with PCOS enrolled; tildacerfont titrated to 200 mg QD vs placebo for 12 weeks.","In patients with elevated baseline DHEAS, geometric mean ratio vs placebo was 0.828 (p=0.020).","SHBG increased 32.9% vs placebo -8.1% (LS mean ratio 1.446, p=0.012).","Tildacerfont well-tolerated; no serious adverse events reported.","Primary endpoint not powered for significance; results suggest therapeutic potential."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227622,"accession_number":"0000950170-24-064561","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-05-24T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Stockholders elect Tiba Aynechi and Kirk Ways as Class I directors; ratify BDO USA as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Tiba Aynechi, Ph.D. elected with 19,761,274 votes for, 639,508 withheld; 10,667,525 broker non-votes.","Kirk Ways, M.D., Ph.D. elected with 19,286,428 votes for, 1,114,354 withheld; 10,667,525 broker non-votes.","BDO USA, LLP ratified as independent auditor for FY 2024 with 30,581,608 votes for, 436,679 against, 50,020 abstentions.","As of March 25, 2024 record date, 41,152,616 shares of common stock outstanding and entitled to vote."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227621,"accession_number":"0000950170-24-058635","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q1 net loss $11.6M; cash $81.2M; CAHmelia-204 data expected Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents $81.2M as of March 31, 2024; expected to fund operations through end of 2025.","Net loss of $11.6M vs $12.8M in Q1 2023; R&D expenses $10.3M (down from $11.7M).","Collaboration revenue of $2.0M from Kaken Pharmaceutical agreement.","CAHmelia-203 analyses show higher GC dose and drug compliance correlate with larger A4 reductions.","Topline data from CAHmelia-204 (adult CAH) and interim dose-ranging from CAHptain-205 (pediatric) expected Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2002000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227620,"accession_number":"0000950170-24-050612","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Spruce Biosciences receives Nasdaq minimum bid price non-compliance notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Spruce on April 26, 2024 that its stock bid price was below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until October 23, 2024) to regain compliance by closing at $1.00+ for 10 consecutive days.","If not compliant, Spruce may transfer to Nasdaq Capital Market for an additional 180-day cure period if it meets other listing standards.","Failure to regain compliance could lead to delisting; the company says it will monitor its stock price and consider options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246421,"accession_number":"0000950170-24-030776","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["2.02","9.01","2.05","8.01"],"status":"ready","headline":"Spruce Biosciences reports CAHmelia-203 fails primary endpoint; cuts 21% workforce","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CAHmelia-203 failed primary endpoint; tildacerfont 200mg QD showed -2.6% placebo-adjusted A4 reduction (non-significant).","Board approved workforce reduction of ~21% and termination of CAHmelia-203; estimated $0.4M cash charges, Q2 2024.","Pediatric CAHptain-205: 73% of patients met A4 or GC reduction endpoint; more rapid clearance than adults.","Cash and equivalents $96.3M at Dec 31, 2023; cost reductions extend runway through end of 2025.","Expects topline CAHmelia-204 in Q3 2024, additional CAHptain-205 data in Q4 2024, FDA meeting in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246420,"accession_number":"0000950170-24-002704","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2024-01-08T23:59:59+00:00","items":["2.02","9.01","7.01","8.01"],"status":"ready","headline":"Spruce Biosciences provides cash update; adult CAH trials enrollment complete; topline data expected March 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and equivalents ~$96M as of Dec 31, 2023; 41.0M shares outstanding.","CAHmelia-203 (N=96) and CAHptain-205 (N=30) enrollment complete, surpassing targets.","CAHmelia-204 enrollment to finish Jan 2024 (N~98); topline results from CAHmelia-203 and CAHptain-205 expected March 2024.","Baseline characteristics: CAHmelia-203 mean A4 1,149 ng/dL on 27 mg/day GC; CAHmelia-204 mean A4 214 ng/dL on 35 mg/day GC.","Cash runway into first half of 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263851,"accession_number":"0000950170-23-062936","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q3 net loss $12.4M; completes enrollment in two key CAH trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $12.4M for Q3 2023 vs. $11.4M same period 2022; revenue $3.1M (Kaken collaboration).","Cash, equivalents, investments $108.0M; expected to fund operations into H1 2025.","Enrollment completed in CAHptain-205 (pediatric, 30 patients) and CAHmelia-203 (adult, >72 patients).","CAHmelia-204 enrollment >75% on track for early Q1 2024 completion.","Topline data expected Q1 2024 for CAHmelia-203 & CAHptain-205; Q3 2024 for CAHmelia-204."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":7202000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281070,"accession_number":"0000950170-23-042420","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2023-08-14T23:59:59+00:00","items":["2.02","9.01","8.01"],"status":"ready","headline":"Spruce Biosciences Q2 net loss $12.8M; reports positive PCOS interim data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.8M for Q2 2023 vs $11.9M for Q2 2022; six-month loss $25.6M.","Cash, equivalents and investments of $120.5M; expected to fund operations into H1 2025.","Collaboration revenue $2.2M from Kaken Pharmaceutical upfront payment recognition.","Interim Phase 2 PCOS data (20 patients) suggests DHEAS reduction with tildacerfont; no serious AEs.","CAHmelia-203 enrollment >75%; CAHmelia-204 nearing 75%; CAHptain cohort 3 screening underway."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":4129000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299777,"accession_number":"0000950170-23-024515","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Spruce Biosciences stockholders elect three Class III directors, ratify BDO USA as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Javier Szwarcberg elected Class III director with 30,521,567 votes for, 32,730 withheld.","Michael Grey elected Class III director with 30,443,905 votes for, 110,392 withheld.","Camilla V. Simpson elected Class III director with 29,471,049 votes for, 1,083,248 withheld.","Stockholders ratified BDO USA as independent auditor for FY 2023: 33,479,638 for, 11,138 against, 5,540 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299776,"accession_number":"0000950170-23-024071","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2023-05-25T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Spruce Biosciences director Dina Chaya resigns; Percival Barretto-Ko appointed to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dina Chaya, Ph.D., C.F.A. resigns from board and committees effective May 25, 2023; not due to any dispute.","Daniel Spiegelman appointed to Nominating Committee; Kirk Ways, M.D., Ph.D. named Chair of Nominating Committee.","Percival Barretto-Ko appointed as Class II director (term to 2025 annual meeting) and to Audit Committee.","Barretto-Ko receives option to purchase 60,000 shares vesting over 3 years, plus annual retainers of $40,000 (director) and $7,500 (audit)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299775,"accession_number":"0000950170-23-021979","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q1 net loss $12.8M; CAH trials near enrollment goals; PCOS study topline Q3 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $118.6M as of March 31, 2023; with Kaken $15M upfront, runway into H1 2025.","Collaboration revenue $2.0M (Kaken deal); R&D $11.7M; net loss $12.8M vs $11.8M YoY.","CAHmelia-204 (adult CAH) 50% enrolled; CAHmelia-203 approaching 75% enrollment.","P.O.W.E.R. PCOS Phase 2 fully enrolled (27 subjects); topline results expected Q3 2023.","Appointed Mo Noursalehi, Ph.D., as SVP of Biometrics; completed $53.6M private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.4,"consensus_revenue_estimate":null,"consensus_revenue_actual":1964000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319880,"accession_number":"0000950170-23-008448","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2023-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences reports FY2022 net loss $46.2M, cash $79.1M; pipeline updates","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $46.2M for FY2022 vs $42.3M in 2021; R&D expenses $35.2M, G&A $12.1M.","Cash, equivalents and investments $79.1M as of Dec 31, 2022; additional $53.6M private placement closed Feb 2023.","CAHmelia-203 in adult classic CAH surpassed 50% enrollment; topline data expected H2 2023.","Strategic partnership with Kaken Pharmaceutical for tildacerfont in Japan; $15M upfront received; cash runway into 1H 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319879,"accession_number":"0000950170-23-002369","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2023-02-09T23:59:59+00:00","items":["1.01","3.02","9.01"],"status":"ready","headline":"Spruce Biosciences raises $53.6M in private placement of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 16.1M shares, 0.8M pre-funded warrants, and 12.7M standard warrants; purchase price $3.17 per share.","Gross proceeds of ~$53.6M; standard warrants exercisable at $3.96 per share for 5 years.","Closing expected on or before February 17, 2023; SVB Securities is placement agent (5% fee).","Company must file registration statement within 30 days of closing to register resale of securities.","Purchasers include Abingworth, HealthCap, Novo Holdings, RiverVest, and Rock Springs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319878,"accession_number":"0000950170-23-000449","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["1.01","2.02","8.01","9.01"],"status":"ready","headline":"Spruce Biosciences licenses tildacerfont to Kaken for Japan; $15M upfront, up to $65M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Exclusive Japan rights for tildacerfont in CAH; $15M upfront, up to ~$65M in development/regulatory/commercial milestones.","Preliminary cash, cash equivalents and investments as of Dec 31, 2022: approximately $79M (unaudited).","Pediatric CAH trial amended: study length increased to 12 weeks plus 2-year open-label extension; age lowered to 2 years.","Additional data to be collected: PK at 50mg and 200mg doses, A4 reduction, GC reduction, and 12-week safety data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338093,"accession_number":"0000950170-22-026009","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Spruce Biosciences terminates Daly City HQ lease, signs new 5-year South San Francisco office lease","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated prior lease at 2001 Junipero Serra Blvd, Daly City effective Dec 31, 2022; receiving $0.6M termination fee and return of $0.2M letter of credit.","Signed new 62-month lease for 6,496 sq ft at 611 Gateway Blvd, Suite 740, South San Francisco starting Jan 1, 2023.","Initial annual base rent ~$0.3M with 3% annual increases; tenant improvement allowance of $129,920.","Lease includes 60-day rent abatement period after commencement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338092,"accession_number":"0000950170-22-024479","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q3 net loss $11.4M; cash $90.4M; enrollment milestones updated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments totaled $90.4M as of Sept 30, 2022.","Net loss for Q3 2022 was $11.4M, flat YoY; R&D expenses $8.8M vs $8.6M.","CAHmelia-203 approaching 50% enrollment; CAHmelia-204 surpassed 25% enrollment.","Appointed Saba Sile, M.D., as VP of Clinical Development from Horizon Therapeutics.","Topline results expected: PCOS trial H1 2023; CAHmelia-203 H2 2023; CAHmelia-204 H2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.49,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355451,"accession_number":"0000950170-22-016467","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences reports Q2 2022 net loss of $11.9M; cash $99.1M; updates on CAH trials and leadership","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.9M for Q2 2022 (vs $11.8M Q2 2021); R&D spend $9.1M, flat YoY.","Cash, equivalents and investments $99.1M as of June 30, 2022.","CAHmelia-203 surpassed 25% enrollment; CAHmelia-204 approaching 25% enrollment.","Appointed P.J. Ramtin as SVP of Business Operations; two new tildacerfont method-of-use patents issued, exclusivity through 2038.","Abstract on Phase 2a CAH data accepted for oral presentation at ICE 2022 (Aug 27)."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.01,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373618,"accession_number":"0000950170-22-010856","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-05-27T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Spruce Biosciences stockholders elect three directors and ratify BDO auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class II directors elected: Dina Chaya, Bali Muralidhar, Daniel Spiegelman.","Ratification of BDO USA as independent auditor for FY2022 passed with 21.15M votes for.","All proposals passed; broker non-votes of ~1.99M shares on director elections."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373617,"accession_number":"0000950170-22-009312","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences Q1 net loss $11.8M; CAHmelia-203 25% enrolled; debt facility amended","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $11.8M in Q1 2022 vs $9.9M in Q1 2021; cash and investments $108.9M as of March 31, 2022.","CAHmelia-203 adult classic CAH study reached 25% enrollment; topline data on track for 2H 2023.","Amended SVB debt facility provides up to $10M credit line in 2022; interest rate cut 50-250 bps.","Appointed Libbie Mansell, Ph.D., as Chief Regulatory and Quality Officer in April 2022.","Tildacerfont patent portfolio expanded with two new U.S. method-of-use patents expiring 2038."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373616,"accession_number":"0000950170-22-005528","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-04-08T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Spruce Biosciences amends CEO Szwarcberg's equity vesting acceleration terms","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amendment to CEO Javier Szwarcberg's offer letter dated April 6, 2022.","Vesting acceleration under Severance Plan for Second Stock Option now only applies to Change in Control with effective date on or after January 3, 2023.","All other terms and conditions of the offer letter remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392306,"accession_number":"0000950170-22-003590","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Spruce Biosciences enters ATM offering for up to $21M in common stock","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Jefferies LLC to sell up to $21M of common stock via at-the-market offerings.","Shares sold at market prices on Nasdaq; Jefferies receives 3% commission on gross proceeds.","Company not obligated to sell; offering may be suspended or terminated upon notice.","Prospectus supplement filed under existing shelf registration effective Feb 11, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392305,"accession_number":"0000950170-22-003573","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-03-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Biosciences reports Q4/FY2021 net loss of $9.2M/$42.3M; cash $121.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments of $121.4M as of Dec 31, 2021; expected to fund operations into Q2 2024.","R&D expenses for FY2021: $30.7M, up from $23.9M in 2020; net loss widened to $42.3M from $29.5M.","Appointed Will Charlton, M.D., M.A.S., as Chief Medical Officer in March 2022; he previously served at 89bio.","Topline safety data from Cohort 1 of Phase 2 pediatric classic CAH study expected by 1H 2023; PCOS Phase 2 topline also by 1H 2023.","CAHmelia-203 (adult classic CAH, poor disease control) topline by 2H 2023; CAHmelia-204 (good disease control) by 2H 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392304,"accession_number":"0001564590-22-000432","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2022-01-05T23:59:59+00:00","items":["2.02","8.01","5.02","9.01"],"status":"ready","headline":"Spruce Biosciences appoints Javier Szwarcberg as CEO, promotes Samir Gharib to President","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Javier Szwarcberg, M.D., MPH, appointed CEO and director effective Jan 3, 2022; succeeds interim CEO Michael Grey, who remains Executive Chairman.","Samir Gharib, MBA, promoted to President while continuing as CFO; salary increased to $430,000 with target bonus of 45%.","Szwarcberg receives options to purchase 1,000,000 shares at $4.59; 750k time-vested over 4 yrs, 250k performance-vested on CAHmelia-204 trial milestones.","Preliminary cash, cash equivalents and investments estimated at $121.4M as of Dec 31, 2021 (unaudited)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410629,"accession_number":"0001564590-21-057008","cik":1683553,"company_name":"SPRUCE BIOSCIENCES, INC.","ticker":"SPRB","form_type":"8-K","filed_at":"2021-11-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Spruce Q3 net loss $11.4M; CAHmelia-203 topline delayed to 2023; CEO retired","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $11.4M for Q3 2021; cash and investments $131.3M as of Sep 30.","R&D expenses $8.6M (Q3 2021) vs $7.8M (Q3 2020); G&A $2.8M vs $1.8M.","CAHmelia-203 topline results now expected in 2023 due to COVID-19 enrollment impact.","Phase 2 trials in pediatric CAH and PCOS remain on track for initiation.","CEO Richard King retired; Executive Chairman Mike Grey appointed Interim CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":132935032.70597737,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2021-11-15T23:59:59+00:00|410629"}